01:38 , Jun 20, 2018 |  BioCentury  |  Finance

Iterating iTeos

With a new office in the U.S. and $75 million in fresh series B funding to support clinical development of at least two candidates, Belgian cancer company iTeos Therapeutics S.A. is considering a U.S. IPO...
04:19 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Galectin's NASH candidate misses in Phase IIb

Galectin Therapeutics Inc. (NASDAQ:GALT) said galactoarabino-rhamnogalacturonate (GR-MD-02) missed the primary endpoint of reducing hepatic venous pressure gradient (HVPG) in the double-blind, U.S. Phase IIb NASH-CX trial to treat patients with non-alcoholic steatohepatitis (NASH) cirrhosis. On the...
22:39 , Dec 5, 2017 |  BC Extra  |  Clinical News

Galectin sinks after NASH candidate misses in Phase IIb

Galectin Therapeutics Inc. (NASDAQ:GALT) fell $0.76 (31%) to $1.72 on Tuesday after reporting that galactoarabino-rhamnogalacturonate (GR-MD-02) missed the primary endpoint of reducing hepatic venous pressure gradient (HVPG) in the Phase IIb NASH-CX trial to treat...
20:38 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

DSMB recommends continuation of Galectin's Phase IIb NASH trial

Galectin Therapeutics Inc. (NASDAQ:GALT) said a DSMB recommended for the third time continuation of the Phase IIb NASH-CX trial evaluating galactoarabino-rhamnogalacturonate (GR-MD-02) in non-alcoholic steatohepatitis (NASH) patients with cirrhosis. Galectin said the DSMB found no...
13:02 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

TD139: Ph IIa data

Data from 24 patients with IPF in the Phase IIa portion of a double-blind, placebo-controlled, U.K. Phase Ib/IIa trial showed that once-daily inhaled TD139 for 2 weeks was well tolerated. Additional data will be presented...
13:01 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

GR-MD-02: Ph IIa data

Data from 5 patients with moderate to severe plaque psoriasis in an open-label, U.S Phase IIa trial showed that 8 mg/kg IV GR-MD-02 every other week led to an average reduction in PASI score of...
20:05 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Patient sample and mouse studies suggest inhibiting LGALS3 could help treat insulin resistance in obesity. Blood levels of LGALS3 were higher in obese patients and mice fed a high-fat diet than in lean subjects...
03:51 , Nov 19, 2016 |  BioCentury  |  Strategy

Adding on in fibrosis

Bristol-Myers Squibb Co.’s deal to license worldwide rights to Nitto Denko Corp.’s antifibrotic siRNA therapy gives the pharma one of industry’s broadest fibrosis pipelines - and the ability to test multiple combinations. BMS now owns...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Galactoarabino-rhamnogalacturonate: Phase IIa data

Top-line data from the double-blind, U.S. Phase IIa NASH- FX trial in 30 patients with NASH with advanced hepatic fibrosis showed that 8 mg/kg GR-MD-02 every 2 weeks missed the primary endpoint of improving liver...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Anti-galectin-3 (LGALS3) mAb-based PET imaging agent to diagnose thyroid cancer

Imaging TECHNOLOGY: PET A mAb-based PET imaging agent targeting LGALS3 could help diagnose thyroid cancer. The agent consists of a rat anti-LGALS3 mAb labeled with the radionuclide 89Zr. In a xenograft mouse model of LGALS3-positive thyroid cancer,...